AERAS

At a Glance
  • Status: Active Consortium
  • Year Launched: 2003
  • Initiating Organization: AERAS
  • Initiator Type: Third-party organization
  • Rare disease
  • Disease focus:
    Tuberculosis
  • Location: International

Abstract

Aeras is a fully integrated, global, nonprofit biotech with capabilities in finance, portfolio management, immunology, assay development, clinical trials, regulatory affairs and policy, advocacy, and resource mobilization, as well as in-house capacity to conduct pilot manufacturing. Serving as a critical translational bridge from the bench to the field Aeras has sponsored and conducted more than 25 clinical vaccine trials enrolling thousands of subjects and is a key partner in six active clinical development programs.

Mission

The Aeras mission is to develop new tuberculosis (TB) vaccines that are affordable and accessible to all who need them.

Structure & Governance

Board of Directors

Financing

Aeras R&D work is funded by key partners worldwide. Funding streams include grants from foundations and governments, investments from industry partners, and co-investments with other organizations, governments, and institutions.

Donor support drives innovation by strengthening and advancing the global pipeline of new TB vaccines, accelerating efforts toward ensuring their availability to all who need them.

Data Sharing

TB vaccine research and development is complex and costly. No one organization or institution can do it alone. Aeras works in partnership with individuals, research organizations, academic institutions, funders, policymakers, and others to advance TB vaccine science. Because of limited resources and the complex biology of TB, it is crucial for scientists in this field to share knowledge and work together.

Some of Aeras’ partners include the following:

Impact/Accomplishment

Aeras’ global partners include academic, public, and private institutions, which work together to build research capacity, install diagnostic and immunology lab infrastructure, and provide training and employment to world-class researchers.

South Africa is particularly poised as a key driver of TB vaccine innovation, because it has the highest incidence of the disease and is well-equipped with world-renowned researchers and infrastructure to conduct TB studies. Aeras’ in-country partners provide primary and follow-up care to communities involved in clinical trials. They educate the local communities and raise awareness about TB and vaccine trials.

Recently, the successful completion of the first large, Phase IIb trial in South Africa of nearly 3,000 infants showed that it is possible to conduct a trial of that scope and magnitude, even though the vaccine did not prove to be more efficacious than the widely used infant vaccine BCG.

Sponsors & Partners

Albert Einstein College of Medicine

Australian AID

Bill & Melinda Gates foundation             

Chinese Center for Disease Control and Prevention

Colorado State University

Columbia University

Cornell University

Crucell                                                                      

Dartmouth University

EDCTP                                                                                        

U.S. Food and Drug Administration

Fudan University

GHIT Fund                                                     

GlaxoSmithKline

Harvard University

Huazhong Agricultural University

Imperial College London

Infectious Disease Research Institute

Institute Pasteur de Lille                    

Johns Hopkins University

London School of Hygiene & Tropical Medicine

Maastricht University

National Institute of Allergy and Infectious Diseases

Okairos                                                          

Oregon Health & Science University

Pontificia Universidad Catolica de Chile

Rijksoverheid                                                     

Rutgers University

Sanofi Pasteur                                                                       

South African Tuberculosis Vaccine Initiative (satvi)

St. Louis University

Statens Serum Institut                        

StopTBPartnership                                                               

Tuberculosis Vaccine Initiative

Tulane University

UKaid

Universita Cattolica del Sacro Cuore

University of Alberta

University of British Columbia

University of California, Berkeley

University of California, Los Angeles

University of Cape Town

University of Maryland

University of Oxford

University of Pittsburgh

University of Sydney

University of Wales

University of Wisconsin

WellcomeTrust                                                                      

Wuhan University


Last Updated: 04/06/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.